Moderna announces positive results for Omicron vaccine / Photo: Joseph Prezioso - AFP
NYSE - LSE
| RBGPF | 1.42% | 76 | $ | |
| CMSD | -0.09% | 23.52 | $ | |
| CMSC | 0.04% | 22.96 | $ | |
| RYCEF | -0.21% | 14.45 | $ | |
| RELX | 1.03% | 49.32 | $ | |
| SCU | 0% | 12.72 | $ | |
| BCC | 0.32% | 83.19 | $ | |
| SCS | 0.06% | 16 | $ | |
| AZN | 1.3% | 74.57 | $ | |
| GSK | 2.21% | 37.58 | $ | |
| VOD | -0.36% | 11.26 | $ | |
| NGG | -0.31% | 72.08 | $ | |
| RIO | 1.12% | 60.77 | $ | |
| BTI | 0.51% | 56.69 | $ | |
| JRI | 0.52% | 13.41 | $ | |
| BCE | 2.23% | 23.78 | $ | |
| BP | 0.91% | 34.19 | $ |
Moderna announces positive results for Omicron vaccine
US biotech company Moderna on Wednesday announced positive results for a new vaccine that targets both the original Covid strain and Omicron.
This so-called "bivalent" vaccine was tested in a trial of more 850 adults, who had all received their first three doses of Moderna's original Spikevax vaccine.
Around half the group then received a fourth dose of Spikevax, while the rest received the bivalent vaccine.
Those who received the bivalent vaccine had significantly higher levels of neutralizing antibodies -- Y-shaped immune system proteins that block the virus -- against Omicron.
On average, these levels were around 75 percent higher in the group who got the bivalent vaccine as a fourth dose compared to those who got the original vaccine as a fourth dose. They also received slightly superior protection to the ancestral strain of Covid compared to Spikevax.
"We are thrilled," said Stephane Bancel, CEO of Moderna in a statement, adding he anticipated this vaccine would be the company's lead candidate for authorization as a booster this fall.
"We want to be as ready as early as August for shipping," he told investors in a call.
Stephen Hoge, the company's president, did concede that antibody levels would be lower against Omicron's sub variants that are now in circulation, but said he believed it was still a superior booster than repeating Spikevax.
The company doesn't yet have data on durability -- how the new vaccine booster will fare three months and six months out.
A panel of Food and Drug Administration experts will meet June 28 to discuss considerations and strategies for boosters in fall and winter.
G.Vitali--GdR
